IperionX closes the week at A$4.08 — down 30% over the past month — yet the most interesting tension is not the price itself but what the ORTEX short score is quietly doing in the background as the stock rebounds off its lows.
The short score has now reached 77.2, its highest reading in the observable history and up from 74.3 just two weeks ago. That matters because short interest itself has barely moved. It edged down 1.5% on the week to 8.8% of the free float — essentially the same range it has occupied all month. The score's continued climb without any meaningful rebuild in short positions confirms what the previous note flagged: the underlying conditions are driving the signal, not fresh short selling. Days-to-cover from the official FINRA data runs above 20, a figure that reflects thin average daily volume rather than extreme crowding. The borrow market has tightened noticeably this week — availability dropped from around 200% to 168% in the last five sessions, a 26% tightening — though at that level there is still meaningful supply relative to what is borrowed. Cost to borrow nudged up 2% on the week to 3.3%, well within a normal range for a small-cap ASX name. The lending market is tightening at the margin, but it is not yet signalling a supply squeeze.
The $100 million strategic investment announced late in the week — flagged in a recent note as validating IperionX's critical minerals processing technology — produced a 6% one-day bounce to A$4.08, but it has not yet reversed the monthly damage. That bounce came against a broadly weak backdrop in the peer group: GG8 fell 11% on the week, SBM dropped 18%, and KAU shed nearly 10%, so the relative performance on Tuesday stood out. Even CMM and ZIM, the two least-affected peers, lost between 2% and 5%.
The insider ownership picture remains a credible support argument. Executive Chairman Todd Hannigan and CEO Taso Arima both bought shares on the open market in late April at prices between A$4.20 and A$4.49 — above where the stock currently trades. Arima added again in late March at A$3.20, closer to the recent lows. Net insider buying over the past 90 days totals approximately $4.1 million in value and 1.4 million shares, with no selling from core management. The lone seller in the recent history was a non-executive director who trimmed in February at A$6.84 — a level the stock has not seen since.
The analyst consensus target of A$6.13 implies roughly 50% upside from current levels, though no recent changes are on record and the data is dated to late June. The factor score picture reinforces the cautious read: the short score ranks in the bottom 1st percentile of the universe, the days-to-cover rank is in the 3rd percentile, and dividend score sits at 30 — a company that offers no income cushion while the capital story plays out.
The earnings history is a genuine concern. Three of the four most recent events produced negative next-day moves: -26%, -16%, and -10% respectively, with the March result extending to a five-day loss of 50%. The one positive outlier — an 8% gain in April with a five-day follow-through of 14% — was the exception rather than the pattern. The next event is scheduled for late September, giving the $100m investment story time to either build credibility or fade. Whether the strategic backing changes the market's post-results reaction function — or whether the short score continues to climb independently of the price — is the question that will define the next chapter.
See the live data behind this article on ORTEX.
Open IPX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
